Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Surges On HIV In Q3, But Investors Pull Back With Myogen Purchase

Executive Summary

The strength of Gilead's HIV portfolio, and particularly its newest addition Atripla, drew investor confidence in the third quarter, with the biopharmaceutical firm gaining 16.2% to reach a quarterly high close of 68.77 Sept. 29

You may also be interested in...



Gilead’s Letairis LEAP Frogs Encysive’s Thelin To PAH Market

Gilead Sciences beat Encysive Pharmaceuticals in a race to bring a second endothelin receptor antagonist to market for the treatment of pulmonary arterial hypertension after FDA simultaneously granted approval to Gilead's Letairis and delayed approval of Encysive's Thelin June 15

Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel